Website www.casuspsychiatrie.nl provides an officially accredited training module that assists psychiatrists in clinical management of psychosis in schizophrenia patients. In conjunction, a direct mail module promotes this website. Every three monts, a new case study is presented.
Aripiprazol (Abilify®) and an a-typical antipsychotic
BMS Netherlands BV
Psychosis in conjunction wirh schizophrenia. Aripiprazol is a partial dopamine D2 receptor-agonist as well as a partial serotonin 5-HT1a-receptor-agonist and a 5HT2a-receptor-antagonist.
Psychiatrists in the Netherlands
Raise awareness in psychiatrists about Abilify® as it was being introduced in the Netherlands. Specific questions that were adressed include:
* What type of patient could benefit the most from this antipsychotic?
* What are the expected effects of treatment?
* What are the possible side-effects and how can they best be addressed?
Abilify® was introduced successfully in the Netherlands, resulting in a quick uptake among psychiatrists. The online e-learning programme has been used by psychiatrists for over 5 years.